Markus Zuber
Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study
Langer I, Gueller U, Viehl C, Moch H, Wight E, Harder F, Oertli D, Zuber M. Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study. Ann Surg Oncol 2009; 16:3366-74.
Sep 4, 2009Axillary lymph node dissection for sentinel lymph node micrometastases may be safely omitted in early-stage breast cancer patients: long-term outcomes of a prospective study
Sep 4, 2009Ann Surg Oncol 2009; 16:3366-74
Langer Igor, Gueller Ulrich, Viehl Carsten T, Moch Holger, Wight Edward, Harder Felix, Oertli Daniel, Zuber Markus
[Follow-up recommendations for patients after curative treatment of invasive breast cancer]
Zuber M, Viehl C, Gueller U, Langer I. [Follow-up recommendations for patients after curative treatment of invasive breast cancer]. Ther Umsch 2008; 65:319-21.
Jun 1, 2008[Follow-up recommendations for patients after curative treatment of invasive breast cancer]
Jun 1, 2008Ther Umsch 2008; 65:319-21
Zuber Markus, Viehl Carsten T, Gueller Ulrich, Langer Igor
Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal
Rosenthal R, Viehl C, Gueller U, Weber W, Adamina M, Spagnoli G, Heberer M, Zuber M. Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal. J Am Coll Surg 2008; 207:95-105.
May 23, 2008Active specific immunotherapy phase III trials for malignant melanoma: systematic analysis and critical appraisal
May 23, 2008J Am Coll Surg 2008; 207:95-105
Rosenthal Rachel, Viehl Carsten T, Gueller Ulrich, Weber Walter P, Adamina Michel, Spagnoli Giulio C, Heberer Michael, Zuber Markus
Interdisciplinary tumour boards in Switzerland: quo vadis?
Lehmann K, Gueller U, Bugnon S, Zuber M. Interdisciplinary tumour boards in Switzerland: quo vadis?. Swiss Med Wkly 2008; 138:123-7.
Mar 8, 2008Interdisciplinary tumour boards in Switzerland: quo vadis?
Mar 8, 2008Swiss Med Wkly 2008; 138:123-7
Lehmann Kuno, Gueller Ulrich, Bugnon Sophie, Zuber Markus
Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study
Langer I, Zuber M, Burger D, Infanger E, Uehlinger U, Wight E, Schnarwyler B, Bronz L, Oertli D, Hess T, Fehr M, Schaer G, Moch H, Koechli O, Berclaz G, Gueller U, Swiss Multicenter Study Group Sentinel Lymph Node in Breast Cancer. Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study. Breast Cancer Res Treat 2008; 113:129-36.
Feb 23, 2008Accuracy of frozen section of sentinel lymph nodes: a prospective analysis of 659 breast cancer patients of the Swiss multicenter study
Feb 23, 2008Breast Cancer Res Treat 2008; 113:129-36
Langer Igor, Zuber Markus, Burger Daniel, Infanger Eduard, Uehlinger Urs, Wight Edward, Schnarwyler Beate, Bronz Lucio, Oertli Daniel, Hess Thomas, Fehr Mathias K, Schaer Gabriel, Moch Holger, Koechli Ossi R, Berclaz Gilles, Gueller Ulrich, Swiss Multicenter Study Group Sentinel Lymph Node in Breast Cancer
Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial
Adamina M, Heberer M, Zuber M, Oertli D, Frey D, Gueller U, Zajac P, Schumacher R, Rosenthal R, Weber W, Spagnoli G. Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial. Contemp Clin Trials 2007; 29:165-81.
Jul 17, 2007Heterologous prime-boost immunotherapy of melanoma patients with Influenza virosomes, and recombinant Vaccinia virus encoding 5 melanoma epitopes and 3 co-stimulatory molecules. A multi-centre phase I/II open labeled clinical trial
Jul 17, 2007Contemp Clin Trials 2007; 29:165-81
Adamina Michel, Heberer Michael, Zuber Markus, Oertli Daniel, Frey Daniel M, Gueller Ulrich, Zajac Paul, Schumacher Reto, Rosenthal Rachel, Weber Walter P, Spagnoli Giulio C
Association of the presence of bone marrow micrometastases with the sentinel lymph node status in 410 early stage breast cancer patients: results of the Swiss Multicenter Study
Langer I, Zuber M, Burger D, Infanger E, Uehlinger U, Wight E, Schnarwyler B, Bronz L, Oertli D, Hess T, Fehr M, Schaer G, Singer G, Berclaz G, Koechli O, Gueller U, Swiss Multicenter Sentinel Lymph Node Study Group in Breast Cancer. Association of the presence of bone marrow micrometastases with the sentinel lymph node status in 410 early stage breast cancer patients: results of the Swiss Multicenter Study. Ann Surg Oncol 2007; 14:1896-903.
Mar 14, 2007Association of the presence of bone marrow micrometastases with the sentinel lymph node status in 410 early stage breast cancer patients: results of the Swiss Multicenter Study
Mar 14, 2007Ann Surg Oncol 2007; 14:1896-903
Langer Igor, Zuber Markus, Burger Daniel, Infanger Eduard, Uehlinger Urs, Wight Edward, Schnarwyler Beate, Bronz Lucio, Oertli Daniel, Hess Thomas, Fehr Mathias K, Schaer Gabriel, Singer Gad, Berclaz Gilles, Koechli Ossi R, Gueller Ulrich, Swiss Multicenter Sentinel Lymph Node Study Group in Breast Cancer
Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients
Langer I, Burger D, Infanger E, Uehlinger U, Wight E, Schnarwyler B, Bronz L, Oertli D, Hess T, Fehr M, Schaer G, Koechli O, Berclaz G, Gueller U, Zuber M. Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients. Ann Surg 2007; 245:452-61.
Mar 1, 2007Morbidity of sentinel lymph node biopsy (SLN) alone versus SLN and completion axillary lymph node dissection after breast cancer surgery: a prospective Swiss multicenter study on 659 patients
Mar 1, 2007Ann Surg 2007; 245:452-61
Langer Igor, Burger Daniel, Infanger Eduard, Uehlinger Urs, Wight Edward, Schnarwyler Beate, Bronz Lucio, Oertli Daniel, Hess Thomas, Fehr Mathias K, Schaer Gabriel, Koechli Ossi R, Berclaz Gilles, Gueller Ulrich, Zuber Markus
Carbon dye staining of sentinel lymph nodes facilitates microstaging of colon cancer patients
Viehl C, Gueller U, Hamel C, Riehle H, Plaass C, Marti W, Oertli D, Zuber M. Carbon dye staining of sentinel lymph nodes facilitates microstaging of colon cancer patients. World J Surg 2006; 30:453-6.
Mar 1, 2006Carbon dye staining of sentinel lymph nodes facilitates microstaging of colon cancer patients
Mar 1, 2006World J Surg 2006; 30:453-6
Viehl Carsten T, Gueller Ulrich, Hamel Christian T, Riehle Hans-Martin, Plaass Christian, Marti Walter R, Oertli Daniel, Zuber Markus
Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy
Langer I, Marti W, Gueller U, Moch H, Harder F, Oertli D, Zuber M. Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy. Ann Surg 2005; 241:152-8.
Jan 1, 2005Axillary recurrence rate in breast cancer patients with negative sentinel lymph node (SLN) or SLN micrometastases: prospective analysis of 150 patients after SLN biopsy
Jan 1, 2005Ann Surg 2005; 241:152-8
Langer Igor, Marti Walter Richard, Gueller Ulrich, Moch Holger, Harder Felix, Oertli Daniel, Zuber Markus
Identification of sentinel lymph nodes in colon cancer depends on the amount of dye injected relative to tumor size
Viehl C, Harder F, Spichtin H, Terracciano L, Stammberger U, Eisner L, Gueller U, Marti W, Hamel C, Zuber M. Identification of sentinel lymph nodes in colon cancer depends on the amount of dye injected relative to tumor size. World J Surg 2003; 27:1285-90.
Nov 6, 2003Identification of sentinel lymph nodes in colon cancer depends on the amount of dye injected relative to tumor size
Nov 6, 2003World J Surg 2003; 27:1285-90
Viehl Carsten T, Harder Felix, Spichtin Hans P, Terracciano Luigi, Stammberger Uz, Eisner Lukas, Gueller Ulrich, Marti Walter R, Hamel Christian T, Zuber Markus
Is positron emission tomography an accurate non-invasive alternative to sentinel lymph node biopsy in breast cancer patients?
Gueller U, Nitzsche E, Moch H, Zuber M. Is positron emission tomography an accurate non-invasive alternative to sentinel lymph node biopsy in breast cancer patients?. J Natl Cancer Inst 2003; 95:1040-3.
Jul 16, 2003Is positron emission tomography an accurate non-invasive alternative to sentinel lymph node biopsy in breast cancer patients?
Jul 16, 2003J Natl Cancer Inst 2003; 95:1040-3
Gueller Ulrich, Nitzsche Egbert, Moch Holger, Zuber Markus
Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer
Gueller U, Heberer M, Harder F, Metzger U, Maurer R, Oertli D, Spagnoli G, Zuber M, Vorburger S, Bösch B, Schnider A, Zajac P, Marti W. Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer. Ann Surg 2002; 236:768-75; discussion 775-6.
Dec 1, 2002Disseminated single tumor cells as detected by real-time quantitative polymerase chain reaction represent a prognostic factor in patients undergoing surgery for colorectal cancer
Dec 1, 2002Ann Surg 2002; 236:768-75; discussion 775-6
Gueller Ulrich, Heberer Michael, Harder Felix, Metzger Urs, Maurer Robert, Oertli Daniel, Spagnoli Giulio Cesare, Zuber Markus, Vorburger Stefan, Bösch Beatrix, Schnider Annelies, Zajac Paul, Marti Walter Richard
Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet!
Gueller U, Harder F, Oertli D, Marti W, Langer I, Moch H, Torhorst J, Viehl C, Schirp U, Nitzsche E, Zuber M. Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet!. Breast Cancer Res Treat 2002; 71:171-3.
Jan 1, 2002Selective axillary surgery in breast cancer patients based on positron emission tomography with 18F-fluoro-2-deoxy-D-glucose: not yet!
Jan 1, 2002Breast Cancer Res Treat 2002; 71:171-3
Gueller Ulrich, Harder Felix, Oertli Daniel, Marti Walter R, Langer Igor, Moch Holger, Torhorst Joachim, Viehl Carsten T, Schirp Udo, Nitzsche Egbert U, Zuber Markus